- $914.60m
- $533.92m
Brief: Solid Biosciences Receives Rare Pediatric Disease Designation From FDA For Gene Therapy Candidate SGT-003
U.S. RESEARCH ROUNDUP- Lennar, Republic Services, Ulta Beauty
Brief: Solid Biosciences Files For Mixed Shelf Of Up To $300 Mln
Brief: Solid Biosciences Announces Licensing Agreement with Armatus Bio for the Use of AAV-SLB101
Brief: Solid Biosciences Files For Offering Of Up To 19.7 Million Shares By The Selling Stockholders - SEC Filing
U.S. STOCKS ON THE MOVE-Halozyme, Scorpio Tankers
U.S. STOCKS ON THE MOVE-Halozyme, Scorpio Tankers, Advanced Micro Devices
U.S. STOCKS ON THE MOVE-InMode, Carrols Restaurant, Tesla
Solid Biosciences up on FDA's 'orphan' tag for Duchenne gene therapy
Brief: Solid Biosciences Patient Dosing Expected To Begin Mid-To-Late Q1 2024
Brief: Solid Biosciences Announces $109 Million Private Placement
Solid Biosciences gains on FDA's 'fast track' tag for Duchenne gene therapy
Solid Biosciences up after FDA nod for gene therapy trial
Solid Biosciences Inc reports results for the quarter ended in June - Earnings Summary
Brief: Solid Biosciences Inc. Q2 net income USD -24.6 million
Solid Biosciences Inc expected to post a loss of $1.53 a share - Earnings Preview
US SEC charges British billionaire Joe Lewis with insider trading
US charges British billionaire Joe Lewis with insider trading (updated)
Solid Biosciences Inc reports results for the quarter ended in March - Earnings Summary